Form 8-K – Item 8.01. AIM ImmunoTech (AIM) disclosed a mid-year update from its ongoing Phase 2 DURIPANC trial evaluating Ampligen (rintatolimod) + AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer patients who achieved stable disease after FOLFIRINOX.
The Company characterizes the interim results as “positive,” but the filing does not provide numerical response, progression-free-survival or safety data. Full details are contained in Exhibit 99.1 (press release) and Exhibit 99.2 (clinical progress deck), which are incorporated by reference.
Positive clinical signal in a high-mortality indication may raise Ampligen’s probability of success and strengthen AIM’s oncology pipeline narrative.
Collaboration with AstraZeneca lends external validation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.